Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1242/dmm.046581 http://scihub22266oqcxt.onion/10.1242/dmm.046581 32887790!7490513!32887790     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32887790&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32887790.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Dis+Model+Mech 2020 ; 13 (9): ä Nephropedia Template TP {{tp|p=32887790|t=2020. Cell and animal models of SARS-CoV-2 pathogenesis and immunity |pdf=|usr=}}{{32887790}} gab.com Text Cell and animal models of SARS-CoV-2 pathogenesis and immunity JO: Dis Model Mech http://www.kidney.de/pget.php?&tw=1&pmid=32887790 #FOAvip The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic. Twit Text FOAVip Cell and animal models of SARS-CoV-2 pathogenesis and immunity ????Dis Model Mech http://www.kidney.de/pget.php?&tw=1&pmid=32887790 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32887790 #FOAvip English Wikipedia <ref>{{Cite pmid|32887790}}</ref> Cell and animal models of SARS-CoV-2 pathogenesis and immunity #MMPMID32887790 Leist SR; Schafer A; Martinez DR Dis Model Mech 2020[Sep]; 13 (9): ä PMID32887790show ga The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic. |Animals[MESH] |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus/drug effects/*immunology/*pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Vaccines[MESH] |Cells, Cultured[MESH] |Coronavirus Infections/drug therapy/*immunology/prevention & control/*virology[MESH] |Disease Models, Animal[MESH] |Host Microbial Interactions[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/*immunology/*virology[MESH] |SARS-CoV-2[MESH] |Species Specificity[MESH] |Tissue Culture Techniques[MESH]Cell and animal models of SARS-CoV-2 pathogenesis and immunity (epmc).pdf DeepDyve Pubget Overpricing